SanBio Company Limited Announces Consolidated Earnings Results for Fiscal Year Ended January 31, 2019; Provides Earnings Guidance for the First Half and Full Year Ending January 31, 2020
March 15, 2019 at 06:00 am
Share
SanBio Company Limited announced consolidated earnings results for Fiscal Year Ended January 31, 2019. For the period, the company reported operating revenue of ¥741 million, operating loss of ¥3,733 million, ordinary loss of ¥2,919 million, loss attributable to owners of parent of ¥2,920 million or ¥60.17 per share, compared to the operating revenue of ¥490 million, operating loss of ¥4,378 million, ordinary loss of ¥3,947 million, loss attributable to owners of parent of ¥3,940 million or ¥86.85 per share for the same period a year ago.
The company provided earnings guidance for the first half of fiscal year 2020. The company forecast operating revenue of ¥284 million, operating loss of ¥3,445 million, ordinary loss of ¥3,196 million, loss attributable to owners of parent of ¥3,197 million or ¥64.29 diluted per share.
The company provided earnings guidance for the year ending January 31, 2020. The company forecast operating revenue of ¥713 million, operating loss of ¥5,887 million, ordinary loss of ¥5,390 million, loss attributable to owners of parent of ¥5,395 million or ¥108.48 diluted per share.
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
SanBio Company Limited Announces Consolidated Earnings Results for Fiscal Year Ended January 31, 2019; Provides Earnings Guidance for the First Half and Full Year Ending January 31, 2020